Background Co-inhibition of poly (ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …

Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …

The relatively high prevalence of alterations in the homologous recombination repair (HRR)
pathway described in advanced prostate cancer provides a unique opportunity to develop …

Preclinical evidence has suggested an interplay between the androgen receptor, which
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

PURPOSE We performed a pooled analysis of multiple trials of poly (ADP-ribose)
polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to …

Importance Targeted therapies based on underlying tumor genomic susceptible alterations
have been approved for patients with metastatic prostate cancer (mPC) and advanced …

Poly (ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling
inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive …

Context PARP inhibitors (PARPi) are established treatments for metastatic castration-
resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency …